Revenue missed analyst estimates by 7.0%. Earnings per share (EPS) exceeded analyst estimates by 21%. Looking ahead, revenue ...

The company ended the quarter with $192 million in cash and equivalents, enough to fund operations past 2027. 2seventy Bio ...

Seventy Bio, Inc. ( (TSVT) ) has released its Q3 earnings. Here is a breakdown of the information 2Seventy Bio, Inc. presented to its ...

CAMBRIDGE, Mass., November 12, 2024--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent ...

TD Cowen analyst Yaron Werber maintained a Hold rating on 2seventy bio (TSVT – Research Report) today. The company’s shares closed ...

Good day and thank you for standing by. Welcome to the 2seventy bio Third Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. After the speakers ...

2Seventy Bio, Inc. ( (TSVT)) has released its Q3 earnings. Here is a breakdown of the information 2Seventy Bio, Inc. presented to its investors. 2seventy bio, Inc. is a biotechnology company ...

When combined with the significant progress our team has made in streamlining our cost structure, 2seventy continues to make meaningful progress on our goal of achieving breakeven operations ...

NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ:TSVT). Such investors are ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the third quarter ended September 30, 2024. “We are very pleased ...